Spurr, Liam F.
Martinez, Carlos A.
Kang, Wenjun
Chen, Mengjie http://orcid.org/0000-0003-1579-087X
Zha, Yuanyuan http://orcid.org/0000-0002-0574-7352
Hseu, Robyn
Gutiontov, Stanley I.
Turchan, William T.
Lynch, Connor M.
Pointer, Kelli B.
Chang, Paul http://orcid.org/0000-0002-9083-1435
Murgu, Septimiu
Husain, Aliya N.
Cody, Brittany
Vokes, Everett E.
Bestvina, Christine M.
Patel, Jyoti D.
Diehn, Maximilian http://orcid.org/0000-0003-2032-0581
Gajewski, Thomas F. http://orcid.org/0000-0001-5727-3972
Weichselbaum, Ralph R.
Chmura, Steven J.
Pitroda, Sean P. http://orcid.org/0000-0003-3056-7991
Funding for this research was provided by:
LUNGevity Foundation
Ludwig Institute for Cancer Research
University of Chicago Comprehensive Cancer Center United-4 A Cure Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R25CA240134-01, GM126553, HG011883)
National Science Foundation (NSF2016307)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Sloan Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 22 February 2022
Accepted: 13 October 2022
First Online: 28 November 2022
Competing interests
: S.M. is an advisor for Olympus America, Medtronic, Johnson & Johnson, ERBE, Boston Scientific, Cook and Pinnacle Biologics. E.E.V. has served as an advisor for AbbVie, AstraZeneca, BeiGene, BioNTech, Eli Lilly, ED Serono, Genentech/Roche, GlaxoSmithKline, Merck and Novartis. C.M.B. reports serving in a consulting or advisory role for AbbVie, AstraZeneca, Genentech, Pfizer, Seattle Genetics and Takeda. J.D.P. serves as an advisor for AstraZeneca, Takeda and Genentech, and receives research funding from Bristol Myers Squibb (institution). M.D. reports personal fees from Roche Sequencing Solutions; grants and personal fees from Astra-Zeneca, Illumina and Genentech; personal fees from Novartis, Gritstone Oncology, BioNTech and Boehringer Ingelheim; grants from Varian Medical Systems; other support from CiberMed Foresight Diagnostics; a patent for ctDNA detection issued and licensed to Roche; and patents for ctDNA detection pending and licensed to Foresight Diagnostics. R.R.W. reports having stock and other ownership interests in Boost Therapeutics, ImmVira, Reflexion Pharmaceuticals, Coordination Pharmaceuticals, Magi Therapeutics and Oncosenescence; serving in a consulting or advisory role for Aettis, AstraZeneca, Coordination Pharmaceuticals, Genus, Merck Serono, NanoProteagen, NKMax America, Shuttle Pharmaceuticals and Highlight Therapeutics, S.L. holds research grants with Varian and Regeneron, and receives compensation (including cost of travel and accommodations and other expenses) from AstraZeneca, Boehringer Ingelheim and Merck Serono. S.J.C. reports participating in the advisory boards for Genentech and AstraZeneca; receiving research support from Bristol Myers Squibb, Merck, EMD Serono and AstraZeneca; and having his spouse who works for Astellas. S.P.P. has patents outside of the submitted work. The remaining authors declare no competing interests.